Fig. 2
From: An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma
oHSV-1 treatment of GL261 tumor-bearing mice significantly improve survival. (A) Experimental setup and treatment schedule is depicted. (B) oHSV-1 intratumoral treatment (black triangles) significantly improved survival compared to animals treated with vehicle (black circles) or left untreated (white squares) with median survival of 38, 26 and 26 days respectively (P < 0.05). Survival was analyzed by Kaplan–Meier method and compared by log-rank Mantel-Cox test